Skye Bioscience Files 8-K on Director/Officer Changes
Ticker: SKYE · Form: 8-K · Filed: Feb 26, 2025 · CIK: 1516551
Sentiment: neutral
Topics: corporate-governance, personnel-changes, filing
TL;DR
Skye Bioscience 8-K: Director/officer changes and new exec comp details filed.
AI Summary
Skye Bioscience, Inc. filed an 8-K on February 26, 2025, reporting on the departure of directors, election of directors, appointment of officers, and compensatory arrangements. The filing also includes financial statements and exhibits. The company was formerly known as Emerald Bioscience, Inc. and Nemus Bioscience, Inc.
Why It Matters
This filing indicates potential shifts in the company's leadership and governance structure, which could impact strategic direction and operational execution.
Risk Assessment
Risk Level: low — This is a routine corporate filing detailing changes in personnel and compensation, not a material event like a merger or significant financial distress.
Key Players & Entities
- Skye Bioscience, Inc. (company) — Registrant
- Emerald Bioscience, Inc. (company) — Former company name
- Nemus Bioscience, Inc. (company) — Former company name
- February 24, 2025 (date) — Earliest event reported date
- February 26, 2025 (date) — Report date
FAQ
What specific items are being reported in this 8-K filing?
This 8-K filing reports on the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements of certain officers. It also includes financial statements and exhibits.
What is the exact date of the earliest event reported in this filing?
The earliest event reported in this filing is dated February 24, 2025.
When was this 8-K form filed with the SEC?
This 8-K form was filed on February 26, 2025.
What were Skye Bioscience, Inc.'s former company names?
Skye Bioscience, Inc. was formerly known as Emerald Bioscience, Inc. (name change on March 25, 2019) and Nemus Bioscience, Inc. (name change on October 30, 2014).
What is the company's state of incorporation and fiscal year end?
The company is incorporated in Nevada and its fiscal year ends on December 31.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on February 26, 2025 regarding Skye Bioscience, Inc. (SKYE).